Unicycive Therapeutics held its Annual Meeting of Stockholders, where the election of directors, appointment of independent registered public accounting firm, approval of Nasdaq 20% Issuance Proposal, approval of Reverse Stock Split Proposal, and approval of amendment and restatement of the 2021 Omnibus Equity Incentive Plan were voted on and approved.